Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Study:

A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC 704865, IND 7921) for Recurrent Sex Cord-Stromal Tumors of the Ovary

Rationale:

Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.

Purpose:

This phase II trial is studying how well bevacizumab works in treating patients with recurrent sex cord-stromal tumors of the ovary.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Ovarian Cancer Biological: bevacizumab Phase 2

Verified by Gynecologic Oncology Group January, 2011

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00748657

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Jubilee Brown, MD., Study Chair
David M. Gershenson, MD.,

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site